Welcome to our dedicated page for Ayala Pharm news (Ticker: ADXS), a resource for investors and traders seeking the latest updates and insights on Ayala Pharm stock.
Ayala Pharmaceuticals, Inc. (OTCQX: ADXS) is a publicly traded, clinical-stage oncology company that focuses on the development and commercialization of small molecule therapeutics. The company primarily targets rare tumors and aggressive cancers through its innovative treatments. Ayala's leading candidate, AL102, is an investigational small molecule gamma secretase inhibitor currently in the Phase 3 RINGSIDE study for the treatment of desmoid tumors. The promising data from Phase 2 shows significant anti-tumor activity and high overall response rates.
Ayala's strategic vision was further enhanced by its merger with Biosight Ltd., which brought aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML), into its portfolio. AL102 has received FDA Fast Track and Orphan Drug Designations for the treatment of desmoid tumors, highlighting its potential impact in oncology.
Recently, Ayala entered into a definitive asset purchase agreement with Immunome, Inc. to sell AL102 and related drug candidate AL101. This agreement, valued at over $50 million, will allow Immunome to advance AL102 through clinical trials and towards potential commercialization. The transaction is expected to be completed by the end of Q3 2024, pending regulatory approvals.
Ayala is committed to advancing its remaining pipeline, which includes aspacytarabine (BST-236) for AML. Despite the sale of its key assets, Ayala continues to focus on developing impactful treatments within oncology, leveraging its expertise and the clinical data it has gathered.
For more information, please visit www.ayalapharma.com.
OS Therapies (NYSE-A: OSTX) has entered into an asset purchase agreement to acquire listeria monocytogenes-based immuno-oncology programs and IP assets from Ayala Pharmaceuticals. The acquisition includes a Phase 2 lung cancer and Phase 1 prostate cancer program, along with direct ownership of IP related to OST-HER2 for osteosarcoma.
The deal, valued at $0.5 million in cash and $7.5 million in OSTX shares, eliminates milestone payments and reduces royalty obligations for OST-HER2. The company recently secured $7.1 million in financing at $4.00 per share, providing cash runway into 2026. The monthly burn rate is approximately $0.4M.
OS Therapies plans to request BLA for OST-HER2 in osteosarcoma in Q2 2025, with potential approval and Priority Review Voucher by end of 2025. The company is prohibited from issuing shares for 6 months and suspended equity line usage below $12.00 per share.
OS Therapies (NYSE-A: OSTX) has entered an asset purchase agreement to acquire listeria monocytogenes-based immuno-oncology programs and IP assets from Ayala Pharmaceuticals. The acquisition includes a Phase 2 lung cancer and Phase 1 prostate cancer program, along with direct ownership of IP related to OST-HER2 for osteosarcoma.
The deal involves a $0.5 million cash payment and $7.5 million in OSTX common shares. The company recently secured $7.1 million in financing at $4.00 per share, providing cash runway into 2026. OS Therapies plans to request BLA for OST-HER2 in osteosarcoma in Q2 2025, with potential FDA approval and Priority Review Voucher by end of 2025.
The agreement eliminates milestone payment obligations and reduces royalty rates for OST-HER2. The company's current burn rate is approximately $0.4M monthly, and they are prohibited from issuing shares for capital raising for 6 months and below $12.00 per share.
Ayala Pharmaceuticals, a clinical-stage oncology company, has filed a Form 15 with the SEC to deregister its common stock under the Exchange Act and suspend reporting obligations. This move will make the company no longer a public reporting entity once the Form 15 is effective.
FAQ
What is the current stock price of Ayala Pharm (ADXS)?
What is the market cap of Ayala Pharm (ADXS)?
What is the primary focus of Ayala Pharmaceuticals?
What are Ayala’s leading candidates under development?
What significant recent transaction has Ayala Pharmaceuticals entered into?
What is AL102 and what phase is it currently in?
What are the FDA designations achieved by AL102?
What was the result of Ayala's merger with Biosight Ltd.?
What is aspacytarabine (BST-236) used for?
What recent clinical milestone has Ayala achieved?
What is the significance of the sale of AL102 to Immunome?
What will Ayala focus on after the sale of AL102?
